FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer

FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer

Source: 
Pharmaceutical Business Review
snippet: 

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction (GEJ).